Low molecular weight fucoidan inhibits hepatocarcinogenesis and nonalcoholic fatty liver disease in zebrafish via ASGR/STAT3/HNF4A signaling
Open Access
- 21 December 2020
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 10 (8) , e252
Abstract
Background: Hepatocellular carcinoma ranks fourth in cancer‐related mortality currently lacks effective therapeutics. Fucoidan is sulfated polysaccharide that is mainly found in brown seaweeds. In this study, we investigated the effects and mechanisms of low molecular weight fucoidan (i.e. oligo‐fucoidan [OF]) preventing hepatocarcinogenesis.Methods: We used [HBx,src], [HBx,src,p53−/+], and [CD36] transgenic zebrafish liver cancer model treated with OF, and performed molecular and histopathological analysis. Transcriptomic and pathways analysis was performed.Results: Decreased expression of lipogenic enzymes, fibrosis markers, and cell cycle/proliferation markers by OF in [HBx,src] and [HBx,src,p53−/+] transgenic fish. Liver fibrosis was decreased as revealed by Sirius Red staining, and the liver cancer formation was eventually reduced by feeding OF. OF was also found to be capable of reducing lipid accumulation and cancer formation in non‐B non‐C Hepatocellular carcinoma (HCC) model in CD36 transgenic zebrafish. Whole‐genome expression analysis showed that 661 genes were up‐regulated, and 451 genes were downregulated by feeding OF. Upregulated genes were mostly found in protein transporter activity, and downregulated genes were enriched with response to extracellular stimulus and metal binding in gene ontology analysis. The driver gene was HNF4A revealed by NetworkAnalyst from OF differential regulated genes at various insults. OF is able to bind the asialoglycoprotein receptor (ASGR) in hepatoma cells, and increased the phosphorylation of signal transducer and activator of transcription 3 (STAT3) in both hepatoma cells and [HBx,src,p53−/+] transgenic fish liver cancer model. Using chromatin‐immunoprecipitation, we found pSTAT3 could associate with the P1 promoter of HNF4A. Knockdown of either ASGR or HNF4A reversed OF mediated anti‐cancer cell proliferation.Conclusions: Taken together, we provide evidence that OF exhibits the anti‐HCC, anti‐steatosis, and anti‐fibrosis effect for liver in zebrafish models, and the anti‐cancer potential of OF attributed to the binding to ASGR and activation of STAT3/HNF4A signaling. OF might be potentially valuable for the management of HCC.Keywords
Funding Information
- National Health Research Institutes (MOST 105‐2319‐B‐400‐001, MG‐109‐PP‐06)
This publication has 66 references indexed in Scilit:
- Epidemiology and surveillance for hepatocellular carcinoma: New trendsJournal of Hepatology, 2020
- Hepatocellular Carcinoma in Asia: A Challenging SituationEuroasian Journal of Hepato-Gastroenterology, 2019
- Hepatocellular CarcinomaNew England Journal of Medicine, 2019
- Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancerWorld Journal of Gastroenterology, 2018
- Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral AgentsGastroenterology, 2017
- Liver Cancer: Connections with Obesity, Fatty Liver, and CirrhosisAnnual Review of Medicine, 2016
- Zebrafish: An Important Tool for Liver Disease ResearchGastroenterology, 2015
- Fucoidan and Cancer: A Multifunctional Molecule with Anti-Tumor PotentialMarine Drugs, 2015
- Non-B, non-C hepatocellular carcinomaInternational Journal of Oncology, 2013
- Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in ChildrenNew England Journal of Medicine, 1997